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therapy, prior authorization, not in formulary) between January 1, 2005 to December
31, 2006 but who subsequently ﬁ lled an SGA or conventional antipsychotic within six 
months of the rejected claim, formed the case group (n  328). Newly initiated anti-
psychotic users who were in health plans with an open formulary and thus did not 
experience rejection of an SGA claim formed the control group (n  1097). All patients
were followed up for 13 months. Cox regression models were used to estimate the 
effect of having rejected claims on all-cause discontinuation of the index drug, deﬁ ned
as discontinuation, add-on or switch. The model controlled for age, sex, co-morbidities, 
geographic locations, index drug, prescription and co-payment. RESULTS: Reasons
for rejected claims were distributed as follows: 1) drug not on formulary (72.9%); 2)
required prior authorization (19.5%); and 3) required step therapy (7.6%). Median 
time to discontinuation was 120 days for the case group and 127 days for the control 
group. The adjusted hazard for discontinuation of the index drug (HR  1.29, 95% 
CI: 1.08–1.53) was signiﬁ cantly higher for patients with rejected initial SGA claims
compared to controls. Co-payments ranging from $20 to $39 were associated with
lower discontinuation compared with copayment ranging from $0 to $4 (HR  0.75, 
95% CI: 0.60–0.93). CONCLUSIONS: New antipsychotic users with rejected initial 
SGA claims due to formulary restrictions were more likely to discontinue their anti-
psychotic drugs compared to users who did not face such restrictions.
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OBJECTIVES: To assess the association between self-perceived copay burden and
medication adherence among patients with schizophrenia. METHODS: Data were 
collected from December 2007 to February 2008 from a web-based consumer panel. 
Adults (age 18) self-reporting a diagnosis of schizophrenia were invited to participate
in the study through self-reported questionnaires on both the internet and through 43 
interview facilities across the US. Inclusion criteria for analysis were: current use of 
an SGA, and no exposure to clozapine or a depot formulation antipsychotic. Adher-
ence was assessed using the MMAS, with general adherence deﬁ ned as MMAS  2, 
and complete adherence deﬁ ned as MMAS  1. Logistic regression models were
developed to assess the effects of self-perceived copay burden on adherence while
adjusting for demographics, substance use, concomitant psychotropic medications,
comorbidities, and health insurance. RESULTS: Of the 351 study respondents who 
met the criteria for analysis, 39% (n  137) perceived experiencing burden from their 
medication copays. Adjusting for covariates, the effects of copay burden on general
adherence approached but did not reach signiﬁ cance (p  0.060). However, patients
who experienced a copay burden were less than half as likely to have complete adher-
ence [OR  0.427; 95% CI: (0.257, 0.711); p  0.001]. Effects of copay burden on 
the individual components of the MMAS varied. Patients with copay burden were 
more likely to forget to take medication [OR  2.058; 95% CI: (1.270, 3.335); p 
0.003] and to discontinue medication when feeling worse [OR  2.000; 95% CI: 
(1.140, 3.507); p  0.016]. Being careless about taking medication and discontinuing
medication when feeling better were not signiﬁ cantly affected by copay burden. 
CONCLUSIONS: Among patients with schizophrenia using SGAs, copay burden is
associated with forgetting to take medication, discontinuing medication when feeling
worse, and lesser likelihood of complete adherence. Less restrictive formularies that
reduce copay burden for SGAs may have a positive effect on medication adherence 
among patients with schizophrenia.
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OBJECTIVES: Treatment of depression is often accompanied by discontinuation and
switching of antidepressant medications. Information on factors predicting persistence
(and avoidance of switching) would thus be of value to medical decision makers. We
assess the impact of demographics, initial dose, prior medications, and comorbidities
on duloxetine treatment persistence for patients with major depressive disorder
(MDD) using retrospective claims data. METHODS: Using the PharMetrics Database,
we studied individuals aged 18–64 who initiated duloxetine treatment between April 
2005 and March 2006, had q1 prior MDD diagnosis, and had continuous insurance
coverage 6 months before and 12 months after initiation. Persistence was deﬁ ned as
q3 months’ continuous duloxetine treatment. Stepwise logistic regression and tree
analyses of demographics, initial dose, prior medications, and comorbidities assessed
predictors of persistence. Sensitivity analysis was done by analyzing factors associated 
with switching to venlafaxine XR or a selective serotonin reuptake inhibitor (SSRI)
within a year of initiating duloxetine. RESULTS: Among 9,148 patients (74.1%
female; mean age  45.6, SD  11.1) who initiated duloxetine treatment, 63.5% had
persistence of duloxetine treatment for q3 months. Regression results showed the most 
signiﬁ cant factors for persistence to be initial dose of q60 mg QD (OR  1.38), age
group of 46–64 yrs (OR vs. age 18–25 yrs  1.63), and venlafaxine XR/SSRI use in 
the prior 3 months (OR  1.64) (all p-values  .001). Sensitivity analysis showed initial 
dose of 60 mg QD was associated with switching from duloxetine (OR  1.22), 
although other factors showed differences from the persistence analysis. CONCLU-
SIONS: The results suggest that for MDD patients, initial dose, age group, and recent 
venlafaxine XR/SSRI use predict persistence on duloxetine treatment. Sensitivity 
analysis on switching showed a consistent effect of initial dose.
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OBJECTIVES: To assess the reasons for discontinuation and for continuation of 
antipsychotic medication in the treatment of schizophrenia from patient and clinician 
perspectives. METHODS: Two measures were developed to assess the Reasons for
Antipsychotic Discontinuation/Continuation (RAD), one from patient’s perspective 
(RAD-I), and the other from clinician’s perspective (RAD-Q). These measures were
administered to patients enrolled in a 12-week study of antipsychotic medication in 
the treatment of schizophrenia (N  630). Reasons for discontinuation and reasons 
for continuation with the assigned antipsychotic during the study were assessed. 
Reported reasons were rated as being a primary reason, very important, somewhat 
important, or of minor importance. The top primary reasons for medication discon-
tinuation and continuation were identiﬁ ed from patient and clinician perspectives, and 
level of concordance between patients’ and clinicians’ reasons was assessed. RESULTS:
The top primary reasons for medication discontinuation differed from the top primary 
reasons for continuation on the medication, with a high level of concordance between 
patients’ and clinicians’ perspectives. The top three primary reasons for medication
discontinuation were insufﬁ cient improvement or worsening of positive symptoms, 
medication-related adverse events, and insufﬁ cient improvement or worsening of 
mood symptoms. The top three primary reasons for medication continuation were
improvement in positive symptoms, subjective perception of improvement, and 
improvement in level of functioning. CONCLUSIONS: Medication efﬁ cacy appears 
to be the core driver of medication continuation and discontinuation, especially with
regard to positive symptoms. Reasons for medication discontinuation differ somewhat 
from reasons for continuation, with a high level of concordance between patients’ and 
clinicians’ perspectives.
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OBJECTIVES: The purpose of this analysis is to quantify the additive burden associ-
ated with experiencing depression symptoms in patients with type-2 diabetes mellitus 
(T2DM). METHODS: Data were from the 2008 US National Health and Wellness 
Survey (NHWS), an annual cross-sectional survey of self-reported health care atti-
tudes, behaviors, disease states, and outcomes of adults aged 18. Analyses were 
limited to respondents self-reporting a diagnosis of T2DM. Depression symptoms were
deﬁ ned as an afﬁ rmative response in the past month to: bothered by feeling down, 
depressed or hopeless; or bothered by having little interest or pleasure in doing things.
Outcomes included health care utilization in the past six months, work productivity 
as measured by the Work Productivity and Activity Impairment (WPAI) questionnaire, 
and SF-12v2 summary scores. Logistic and linear regression models were developed
to assess independent effects of depression on outcomes, while adjusting for demo-
graphics and co-morbidity. RESULTS: Among patients with T2DM, 38% self-reported 
depression symptoms. Adjusting for demographics and co-morbidity, patients with
depression symptoms were 1.7 (p  0.001) times as likely to visit the emergency room, 
1.6 (p  0.001) times as likely to be hospitalized, and had 2.2 (p  0.001) additional 
provider visits compared to T2DM patients without depression symptoms. Depression
symptoms were also associated with 21.4% (p  0.001) greater impairment in daily
activities and a decrease in SF-12v2 physical and mental summary scores of 4.0 (p 
0.001) and 12.7 (p  0.001) points, respectively. Among patients who were employed
full-time, depression symptoms were associated with 4.3% (p  0.001) greater missed 
work time, 15.2% (p  0.001) greater lost productivity while working, and 13.4% (p
 0.001) greater overall work impairment. CONCLUSIONS: In patients with T2DM, 
depression symptoms were associated with signiﬁ cant burden on health care utiliza-
tion, work productivity, and health-related quality of life. Proper treatment of both
T2DM and co-morbid depression in this population may reduce humanistic and eco-
nomic burden of disease.
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OBJECTIVES: Type 2 Diabetes Mellitus (T2DM) is an adult-onset, chronic, metabolic 
disorder that affects approximately 23.5 million adults in the United States and 
requires management with daily medications, blood glucose monitoring, regular 
HbA1c assessments, diet, and exercise. If T2DM patients also have difﬁ culties
with planning, working memory, and organization, their health problems may 
be compounded due to inappropriate management of their chronic health condition. 
The current study sought to estimate the prevalence of T2DM patients with the 
